Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
AUROBINDO PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
AUROBINDO PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 715 | 331 | - | |
Low | Rs | 397 | 238 | - | |
Sales per share (Unadj.) | Rs | 424.2 | 98.3 | - | |
Earnings per share (Unadj.) | Rs | 32.9 | -24.8 | - | |
Cash flow per share (Unadj.) | Rs | 54.1 | -20.5 | - | |
Dividends per share (Unadj.) | Rs | 3.00 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 458.1 | 77.2 | - | |
Shares outstanding (eoy) | m | 585.94 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 2.9 | 45.3% | |
Avg P/E ratio | x | 16.9 | -11.5 | -147.2% | |
P/CF ratio (eoy) | x | 10.3 | -13.9 | -74.1% | |
Price / Book Value ratio | x | 1.2 | 3.7 | 32.9% | |
Dividend payout | % | 9.1 | 0 | - | |
Avg Mkt Cap | Rs m | 325,753 | 48,025 | 678.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 35,223 | 3,014 | 1,168.6% | |
Avg. sales/employee | Rs Th | 0 | 3,866.4 | - | |
Avg. wages/employee | Rs Th | 0 | 702.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -974.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 248,554 | 16,598 | 1,497.5% | |
Other income | Rs m | 2,906 | 116 | 2,500.0% | |
Total revenues | Rs m | 251,460 | 16,715 | 1,504.4% | |
Gross profit | Rs m | 37,070 | -2,876 | -1,288.8% | |
Depreciation | Rs m | 12,446 | 716 | 1,737.3% | |
Interest | Rs m | 1,405 | 450 | 312.4% | |
Profit before tax | Rs m | 26,125 | -3,926 | -665.4% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,849 | 245 | 2,791.6% | |
Profit after tax | Rs m | 19,277 | -4,182 | -460.9% | |
Gross profit margin | % | 14.9 | -17.3 | -86.1% | |
Effective tax rate | % | 26.2 | -6.2 | -419.5% | |
Net profit margin | % | 7.8 | -25.2 | -30.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 214,599 | 12,157 | 1,765.2% | |
Current liabilities | Rs m | 114,938 | 6,840 | 1,680.4% | |
Net working cap to sales | % | 40.1 | 32.0 | 125.2% | |
Current ratio | x | 1.9 | 1.8 | 105.1% | |
Inventory Days | Days | 21 | 111 | 18.6% | |
Debtors Days | Days | 66 | 124 | 52.9% | |
Net fixed assets | Rs m | 176,668 | 7,086 | 2,493.1% | |
Share capital | Rs m | 586 | 77 | 760.3% | |
Net worth | Rs m | 268,399 | 13,028 | 2,060.2% | |
Long term debt | Rs m | 6,190 | 4,578 | 135.2% | |
Total assets | Rs m | 392,125 | 24,611 | 1,593.3% | |
Interest coverage | x | 19.6 | -7.7 | -253.4% | |
Debt to equity ratio | x | 0 | 0.4 | 6.6% | |
Sales to assets ratio | x | 0.6 | 0.7 | 94.0% | |
Return on assets | % | 5.3 | -15.2 | -34.8% | |
Return on equity | % | 7.2 | -32.1 | -22.4% | |
Return on capital | % | 10.0 | -19.8 | -50.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,868 | 1,417 | 1,684.6% | |
From Investments | Rs m | -39,778 | -435 | 9,143.7% | |
From Financial Activity | Rs m | 18,144 | 4,155 | 436.7% | |
Net Cashflow | Rs m | 2,298 | 5,137 | 44.7% |
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: PARNAX LAB JUBILANT PHARMOVA DIVIS LABORATORIES MANKIND PHARMA SAROJA PHARMA INDUSTRIES INDIA LTD.
Indian share markets continued the momentum as the session progressed and ended on firm footing.